Commercialization Strategies for Communicating Evidence of a Therapy’s Value

11:00 AM - 11:55 AM, Monday, February 10, 2020 ・ Lyceum Complex
Small and mid-sized biotech companies commercially launched 42% of U.S. new drug approvals in 2018, quadrupling their share from a decade prior compared with older global pharmaceutical companies, according to IQVIA Institute analysis. As these emerging biotechs pursue commercial independence, leadership teams must learn to make compelling value reimbursement arguments, negotiate with payers, and form skilled sales teams. This panel will discuss how to develop such capabilities in alignment with R&D efforts and the Real World Evidence-based resources that might support such strategies.
Moderator
photo
Correspondent
Business Insider
Speakers
photo
President and CEO
Synlogic
photo
CEO
Aetion
photo
SVP, Head of Medical Affairs
Alnylam Pharmaceuticals
photo
Partner
Aisling Capital
photo
Board Member
Urogen